Loading…
GeoVax Labs, Inc. is projected to decline to $0.6419 by 2027, a -11% move from its current price of $0.7247. GOVX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6847 | $0.7254 | $0.7686 | +0.10% |
| Aug 6 | $0.6691 | $0.7261 | $0.788 | +0.20% |
| Aug 7 | $0.6576 | $0.7268 | $0.8034 | +0.29% |
| Aug 8 | $0.6481 | $0.7275 | $0.8167 | +0.39% |
| Aug 9 | $0.6399 | $0.7282 | $0.8287 | +0.49% |
| Aug 10 | $0.6327 | $0.729 | $0.8398 | +0.59% |
| Aug 11 | $0.6262 | $0.7297 | $0.8502 | +0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6262 | $0.7297 | $0.8502 | +0.69% |
| Week 2 | $0.5918 | $0.7347 | $0.9121 | +1.38% |
| Week 3 | $0.5676 | $0.7397 | $0.9641 | +2.07% |
| Week 4 | $0.5485 | $0.7448 | $1.01 | +2.77% |
| Week 5 | $0.5327 | $0.7499 | $1.06 | +3.48% |
| Week 6 | $0.5191 | $0.755 | $1.10 | +4.18% |
| Week 7 | $0.5072 | $0.7602 | $1.14 | +4.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers in the United States. Its pipeline includes GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel therapy in Phase 1/2 for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
The company also offers GEO-MVA-MUC1, a vaccine candidate in preclinical trial for solid tumor cancers, along with GEO-ZM02 in preclinical trials for Zika, GEO-EMO1-Z for Ebola Zaire, GEO-EMO1-S for Ebola Sudan, GEO-MM01 for Marburg, and GEO-MVA for Mpox and smallpox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health and the U.S. Department of Defense.
GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotech company focused on vaccines and immunotherapies, with several candidates spanning infectious diseases and cancer. The company’s pipeline and collaborations indicate a broad research and development footprint within the United States.
It operates in a high-risk, high-uncertainty sector given the early-stage nature of many programs and ongoing clinical testing. The current price and market cap provide a snapshot of market valuation, not a guarantee of future performance.
A major floor 70.3% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 90.4% above — a clean break opens room to run.
A major ceiling 402.3% above — clearing it would confirm fresh momentum.
Key GOVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GOVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7138 | Buy | $0.7222 | Buy |
| MA 10 | $0.8056 | Sell | $0.7939 | Sell |
| MA 20 | $0.951 | Sell | $0.9268 | Sell |
| MA 50 | $1.41 | Sell | $1.22 | Sell |
| MA 100 | $1.41 | Sell | $2.04 | Sell |
| MA 200 | $4.19 | Sell | $6.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.53 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -111.59 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -32.57 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.93 | Sell |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 15.77 | Buy |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.66 | Buy |
| ADX (14) | 29.97 | Sell |
| ATR (14) | 0.06 | Info |
The current technical backdrop shows bearish sentiment. The RSI14 is 30, signaling tentative downside pressure relative to neutral conditions. The stock trades below key moving averages, with the SMA50 at $1.52 and the SMA200 at $4.60, highlighting near-term weakness.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.681 | $0.7247 | $1.01 | 0% | Neutral | |
| $0.4677 | $0.6419 | $0.9519 | -11% | Neutral | |
| $0.4375 | $0.6386 | $1.01 | -12% | Neutral | |
| $0.3615 | $0.5561 | $0.9244 | -23% | Bearish | |
| $0.3776 | $0.6091 | $1.05 | -16% | Bearish | |
| $0.4974 | $0.8385 | $1.50 | +16% | Neutral | |
| $0.4635 | $0.8151 | $1.51 | +12% | Neutral | |
| $0.4891 | $0.8959 | $1.70 | +24% | Bullish | |
| $0.4595 | $0.8756 | $1.71 | +21% | Bullish | |
| $0.319 | $0.6318 | $1.26 | -13% | Neutral | |
| $0.4777 | $1.06 | $2.33 | +46% | Bullish | |
| $0.8876 | $1.97 | $4.54 | +172% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.681 | $0.7247 | $0.8725 | +0.00% |
| September 2026 | $0.6004 | $0.7298 | $0.9255 | +0.70% |
| October 2026 | $0.6427 | $0.7922 | $1.03 | +8.55% |
| November 2026 | $0.6356 | $0.7924 | $1.04 | +0.03% |
| December 2026 | $0.6021 | $0.7585 | $1.01 | -4.28% |
Click any year to see its month-by-month GOVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GOVX is projected to trade between $0.681 and $1.01, averaging $0.7247 — a potential gain of 0% from today's $0.7247. A consolidation phase looks the most probable path here.
GeoVax Labs, Inc.'s 2027 outlook centres on $0.6419, within a $0.4677 to $0.9519 range. That is -11% versus the projected 2026 average. That marks a -11% change versus current levels. Price action looks broadly range-bound.
By 2028, GOVX could reach as high as $1.01, with a base case around $0.6386 and support toward $0.4375 — roughly -12% from $0.7247. A consolidation phase looks the most probable path here.
Expect GOVX to range from $0.3615 to $0.9244 through 2029. The $0.5561 average target implies a -23% move from current prices. That is -13% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The GOVX price prediction for 2030 points to an average of $0.6091 (low $0.3776, high $1.05) — a potential decline of -16% on today's $0.7247. Expect choppier, lower action through this leg of the cycle.
In 2031, GOVX is projected to trade between $0.4974 and $1.50, averaging $0.8385 — a potential gain of +16% from today's $0.7247. That is up +38% on the projected 2030 average. Price action looks broadly range-bound.
GeoVax Labs, Inc.'s 2032 outlook centres on $0.8151, within a $0.4635 to $1.51 range. That is -3% versus the projected 2031 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, GOVX could reach as high as $1.70, with a base case around $0.8959 and support toward $0.4891 — roughly +24% from $0.7247. Momentum favours further upside here.
Expect GOVX to range from $0.4595 to $1.71 through 2034. The $0.8756 average target implies a +21% move from current prices. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The GOVX price prediction for 2035 points to an average of $0.6318 (low $0.319, high $1.26) — a potential decline of -13% on today's $0.7247. Price action looks broadly range-bound.
In 2040, GOVX is projected to trade between $0.4777 and $2.33, averaging $1.06 — a potential gain of +46% from today's $0.7247. That is up +68% on the projected 2035 average. Buyers look set to stay in control over this stretch.
GeoVax Labs, Inc.'s 2050 outlook centres on $1.97, within a $0.8876 to $4.54 range. That is up +86% on the projected 2040 average. That marks a +172% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GOVX today (≈ 1,379.88133 GOVX) could be worth
$2,721.61
+$1,721.61 (+172%) by 2050 · US Dollar
Based on the average projected GOVX price of $1.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GOVXwould be worth at today's price.
$1,000 invested in GOVX on Jul 31, 2025 (≈ 55.555556 GOVX) would be worth
$40.26
-$959.74 (-96.0%) today · 0.04× · US Dollar
Based on a GOVX entry price of $18 vs. today's $0.7247.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.731 | $991.38 | -0.9% |
| 1 month ago | $1.26 | $575.16 | -42.5% |
| 3 months ago | $1.15 | $627.45 | -37.3% |
| 6 months ago | $2.8 | $258.82 | -74.1% |
| 1 year ago | $18 | $40.26 | -96.0% |
| All time (5.0y) ago | $1,638.75 | $0.44 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GOVX forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $7.29M
The multi-year outlook table shows a path from neutral to bullish momentum at various points. In 2026 the min, avg, and max are $0.7312, $0.7312, and $1.02 with ROI 0 and sentiment Neutral. By 2027 the avg is $0.6546 (min $0.4761, max $0.9729) with ROI -10.5 and Neutral sentiment.
The sequence continues through 2029 with a declining average and negative ROI, then turns positive again around 2031 with an avg of $0.8307 and ROI 13.6, followed by 2032 at $0.8349 average with ROI 14.2 and 2033 at $0.9155 average with ROI 25.2. The forecast shows continued improvement toward 2040 with an average price of $1.06 and ROI 44.4, and by 2050 an average price of $2.02 with ROI 176.3, both labeled Bullish. These figures illustrate a long-tail upside potential despite earlier downsides, but they are estimates and not guarantees.
The dataset also lists high volatility (annualized volatility 100%), underscoring the substantial risk and price swings inherent in the asset.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.3865, avg $0.6242, max $1.08 with ROI -14.6 and Neutral sentiment.
Near term is Neutral to Bearish in the forecast, with a path to potential upside later in the horizon (2031-2050) and a high-risk profile reflected in the 100% annualized volatility. The latest data shows current price $0.7312 and market cap $3.81M, with long-run upside possible but not guaranteed.
Yes. The forecast lists several year maxima above $1, including 2030 max $1.08, 2031 max $1.49, 2032 max $1.54, 2033 max $1.74, 2040 max $2.32, and 2050 max $4.65.
Sentiment is Bearish with RSI 14 at 30. The SMA50 is $1.52 and the SMA200 is $4.60. Support is at $0.84 and resistance at $1.38, with the 30-day price range from $0.4859 to $1.10.
Current price is $0.7312 and market cap is $3.81M, with a rank of 5111.
GeoVax Labs, Inc. Community Discussion
0Share your GeoVax Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.